GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Research & Development

LTRN (Lantern Pharma) Research & Development : $15.43 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Lantern Pharma's Research & Development for the three months ended in Sep. 2024 was $3.72 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $15.43 Mil.


Lantern Pharma Research & Development Historical Data

The historical data trend for Lantern Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantern Pharma Research & Development Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 0.95 2.24 7.57 8.60 11.89

Lantern Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.21 3.57 4.25 3.89 3.72

Lantern Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantern Pharma  (NAS:LTRN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Lantern Pharma Research & Development Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantern Pharma Business Description

Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini director 1223 FOXGLOVE LANE, WEST CHESTER PA 19380

Lantern Pharma Headlines